Compared to placebo, PCSK9 inhibitors (alirocumab and evolocumab) reduced the risk of CVD, MI, stroke (combination of ischemic and hemorrhagic events), and all-cause death (high-certainty evidence) (for alirocumab). The gene discussed is PCSK9; the disease is Stroke.